A recent study also demonstrated that combined treatment with the CDK4/6 inhibitor and a novel distinctive structure PI3Kα inhibitor through arrest enhancing G1-phase and enhancing inhibition of Rb phosphorylation to against KRAS-mutated NSCLC (54). This evidence concerns the gene CDK4 and non-small cell lung carcinoma.